What is Needham's price target for ITCI?

Needham's latest stated price target for Intra-Cellular Therapies Inc. (ITCI) is $65, from its action on Feb 25, 2022.

What is Needham's rating on ITCI?

Needham rates ITCI Buy, a bullish rating, as of Feb 25, 2022.

When did Needham last change its view on ITCI?

On Feb 25, 2022, Needham raises its price target to $65 from $59, keeps Buy.

Needham ITCI price target and rating history

Intra-Cellular Therapies Inc. (ITCI) · Health Care

Needham rates Intra-Cellular Therapies Inc. (ITCI) Buy with a $65 price target, as of its latest action on Feb 25, 2022. It has published 3 rating actions on ITCI since September 2021, including 0 upgrades and 0 downgrades.

Current rating: Buy
Price target: $65
Median target, all firms: Too few
Actions on ITCI: 3

Needham price target on ITCI

Needham price target on ITCI, each point a stated target, September 2021 to February 2022.

Every Needham rating on ITCI

Feb 25, 2022
ReiterateNeedham raises its price target to $65 from $59, keeps Buy
Dec 20, 2021
ReiterateNeedham raises its price target to $59 from $55, keeps Buy
Sep 23, 2021
InitiateNeedham starts coverage at Buy, price target $55

Questions about Needham and ITCI

What is Needham's price target for ITCI?: Needham's latest stated price target for Intra-Cellular Therapies Inc. (ITCI) is $65, from its action on Feb 25, 2022.
What is Needham's rating on ITCI?: Needham rates ITCI Buy, a bullish rating, as of Feb 25, 2022.
When did Needham last change its view on ITCI?: On Feb 25, 2022, Needham raises its price target to $65 from $59, keeps Buy.

More ITCI rating histories

RBC Capital Markets3

All Needham ratings ITCI news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.